{"id":"W1984238071","doi":"10.1097/01.jto.0000283088.78970.9b","title":"PRS-03: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Gemcitabine; Tolerability; Internal medicine; Hazard ratio; Lung cancer; Clinical endpoint; Cisplatin; Oncology; Randomization; Performance status; Chemotherapy; Randomized controlled trial; Confidence interval; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002332761,0.001946325,0.003648109,0.0006099423,0.0005279326,0.001636539,0.002151391,0.001754351,0.007061408],"category_scores_gemma":[0.001583376,0.001036776,0.002707892,0.0007466179,0.001805465,0.001654038,0.0005432218,0.006395552,0.001764077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001488311,"about_ca_system_score_gemma":0.002616599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002974823,"about_ca_topic_score_gemma":0.006456953,"domain_scores_codex":[0.9993761,0.0003349427,0.00002989454,0.0001051983,0.00003893313,0.0001149163],"domain_scores_gemma":[0.9990434,0.0001863023,0.0001536908,0.00007170724,0.00004466817,0.0005002694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8826596,0.03196377,0.002087511,0.000754822,0.001688494,0.0001007531,0.0002487506,0.003232094,0.01173599,0.0003911964,0.003831815,0.06130528],"study_design_scores_gemma":[0.7600471,0.2316734,0.003818215,0.00002872952,0.0005045052,0.000137641,0.00006262371,0.001137428,0.001192193,0.0002084781,0.001164156,0.00002556171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875547,0.002661127,0.0007103588,0.001218316,0.0003573459,0.002639676,0.001989205,0.0003119208,0.002557387],"genre_scores_gemma":[0.9841452,0.002847838,0.002315468,0.001275957,0.0002576716,0.002540629,0.002626459,0.0001028897,0.003887813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007061408,"threshold_uncertainty_score":0.02362281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02351774974673011,"score_gpt":0.4348036259945223,"score_spread":0.4112858762477922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}